Cargando…

Gathering and Exploring Scientific Knowledge in Pharmacovigilance

Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of interactions amongst drugs and their effects in the human organism. However, technological advances in this field have been slowing down over the last decade due to miscellaneous legal, et...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Pedro, Nunes, Tiago, Campos, David, Furlong, Laura Ines, Bauer-Mehren, Anna, Sanz, Ferran, Carrascosa, Maria Carmen, Mestres, Jordi, Kors, Jan, Singh, Bharat, van Mulligen, Erik, Van der Lei, Johan, Diallo, Gayo, Avillach, Paul, Ahlberg, Ernst, Boyer, Scott, Diaz, Carlos, Oliveira, José Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859628/
https://www.ncbi.nlm.nih.gov/pubmed/24349421
http://dx.doi.org/10.1371/journal.pone.0083016
Descripción
Sumario:Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of interactions amongst drugs and their effects in the human organism. However, technological advances in this field have been slowing down over the last decade due to miscellaneous legal, ethical and methodological constraints. Pharmaceutical companies started to realize that collaborative and integrative approaches boost current drug research and development processes. Hence, new strategies are required to connect researchers, datasets, biomedical knowledge and analysis algorithms, allowing them to fully exploit the true value behind state-of-the-art pharmacovigilance efforts. This manuscript introduces a new platform directed towards pharmacovigilance knowledge providers. This system, based on a service-oriented architecture, adopts a plugin-based approach to solve fundamental pharmacovigilance software challenges. With the wealth of collected clinical and pharmaceutical data, it is now possible to connect knowledge providers’ analysis and exploration algorithms with real data. As a result, new strategies allow a faster identification of high-risk interactions between marketed drugs and adverse events, and enable the automated uncovering of scientific evidence behind them. With this architecture, the pharmacovigilance field has a new platform to coordinate large-scale drug evaluation efforts in a unique ecosystem, publicly available at http://bioinformatics.ua.pt/euadr/.